

## Letrozole in advanced breast cancer: the PO25 trial

Henning T. Mouridsen

Published online: 8 May 2007  
© Springer Science+Business Media B.V. 2007

### Erratum to: Breast Cancer Research and Treatment DOI 10.1007/s10549-007-9527-6

Unfortunately an incorrect Table 1 was published. Please find below the correct table.

**Table 1** Time to progression in different patient subgroups [57]

Subgroup		Letrozole	Tamoxifen
Dominant disease site: soft tissue	<i>n</i>	113	115
	Median TTP	12.1 months	6.4 months
Dominant disease site: bone	<i>n</i>	145	131
	Median TTP	9.5 months	6.3 months
Dominant disease site: viscera	<i>n</i>	195	208
	Median TTP	8.3 months	4.6 months
Patients who had received prior Antiestrogen	<i>n</i>	84	83
	Median TTP	8.9 months	5.9 months
	Hazard ratio (95% CI) <sup>a</sup>	0.60 (0.43, 0.84)	
HR-positive	<i>n</i>	294	305
	Median TTP	9.4 months	6.0 months
	Hazard ratio (95% CI) <sup>a</sup>	0.69 (0.58, 0.83)	
HR-unknown	<i>n</i>	159	149
	Median TTP	9.2 months	6.0 months
	Hazard ratio (95% CI) <sup>a</sup>	0.77 (0.60, 0.99)	

TTP, time to progression; CI, confidence interval; HR, hormone receptor

<sup>a</sup> Hazard ratios <1.0 indicate superiority for letrozole relative to tamoxifen

The online version of the original article can be found at  
<http://dx.doi.org/10.1007/s10549-007-9527-6>

H. T. Mouridsen (✉)  
Department of Oncology, Rigshospitalet, Copenhagen  
University Hospital, Blegdamsvej 9, 2100 Copenhagen,  
Denmark  
e-mail: hmouridsen@rh.dk